Relugolix not checked

Qilu Pharmaceutical

FollowEvery change as it happens, and a Monday email
Next date
None yet
 
Trials
5 active
5 in total · 4 in the EU
Targets
 

What this is

How it works
Gonadotropin Releasing Hormone Receptor Antagonist FDA class
How it’s given
“Relugolix (0 mg) tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor. megestrol acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor. medroxyprogesterone acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size,…”In the company’s words, NCT06671548 on ClinicalTrials.gov
Tested for
Heavy Menstrual Bleeding, Uterine Fibroids
Main trialPhase 3
“The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids. The main question\[s\] it aims to answer are: * the benefit of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids * the safety of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids”In the company’s words, NCT06671548 on ClinicalTrials.gov

Other drugs for Heavy Menstrual Bleeding

All 3 drugs for Heavy Menstrual Bleeding

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 12 Nov 2026 Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase 3Authorised not given Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.
Phase 3Authorised not given EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE)
Phase 2Authorised not given Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO)
Phase 2Authorised not given REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermediate-Risk Prostate Cancer: a Special Focus on Quality of Life and Erectile Function Recovery
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Relugolix

Following is part of Solo: you see every change to Relugolix the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in